St. Jude Medical, Inc. (STJ) Maintains An Accumulate Rating

Analysts Brooke E. West and John D. Crowther at Craig-Hallum Capital Group LLC have maintained an Accumulate rating for St. Jude Medical, Inc. (NYSE: STJ). Analysts have also maintained the price target of $41 for St. Jude Medical, Inc.

The management at St. Jude has reiterated its guidance of 7%-11% growth in sales, and 12%-14% growth in EPS in 2010. According to analysts, this would require the company to have a growth at or above market rates for all business segments.

Analysts expect the company to maintain share in its four markets. However, analysts believe that the company will struggle to achieve even the low-end of its sales guidance range for 2010 as it is heavily weighted towards significant growth in the back half of the year, a reacceleration of the US CRM business, and share gains in A-Fib.